Kurs
-0,67%
Kurs
-0,67%
Open
73,10
High
75,00
Low
71,90
Close
73,80
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
8,04 MNOK
Likviditet
8,04 MNOK
Rel. mcap
0,92%
Antal aktier
109 802
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2026-02-25 | 06:30 | Bokslutskommuniké 2025 |
| 2025-11-26 | 00:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 00:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | N/A | Årsstämma |
| 2025-05-14 | 00:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-26 | 06:30 | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-08-23 08:30:00
Oslo, Norway, August 23, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, will hold a webcast to discuss the results for the first half
of 2021 on August 26, 2021 at 10 am CEST.
The webcast will be in English and may be viewed here:
https://forms.office.com/r/7c9HHCDRPT. Further, the slide presentation will be
available on Vaccibody's website at https://www.vaccibody.com
About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Vaccibody's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen-specific immune responses
and elicit efficacious clinical responses. Its lead product candidates include
VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to
Genentech and is in Phase Ib for the treatment of locally advanced and
metastatic tumors and Phase I/IIa for the treatment of melanoma, lung-, head and
neck, renal-, and bladder cancer